

Ana B Pavel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2632807/publications.pdf>

Version: 2024-02-01

64
papers

3,070
citations

147801

31
h-index

182427

51
g-index

64
all docs

64
docs citations

64
times ranked

2466
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 872-881.e6.	1.2	265
2	Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 122, 99-110.e6.	1.0	150
3	GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 482-493.e7.	2.9	144
4	Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 142-154.	2.9	135
5	Use of Tape Strips to Detect Immune and Barrier Abnormalities in the Skin of Children With Early-Onset Atopic Dermatitis. <i>JAMA Dermatology</i> , 2019, 155, 1358.	4.1	113
6	Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 199-212.	2.9	113
7	The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 690-699.	1.2	103
8	Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 144-156.	2.9	99
9	Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1011-1024.	2.9	95
10	A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 379-387.	1.2	92
11	A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1063-1072.	0.7	84
12	Crisaborole and atopic dermatitis skin biomarkers: An inpatient randomized trial. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1274-1289.	2.9	82
13	The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 510-519.	1.2	76
14	Atopic dermatitis in Chinese patients shows TH2/TH17 skewing with psoriasiform features. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1013-1017.	2.9	72
15	The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 148-163.	2.9	72
16	Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 215-228.	2.9	70
17	Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 394-397.	2.9	69
18	Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1369-1380.	2.9	66

#	ARTICLE	IF	CITATIONS
19	Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 314-325.	5.7	61
20	Th2/Th1 Cytokine Imbalance Is Associated With Higher COVID-19 Risk Mortality. <i>Frontiers in Genetics</i> , 2021, 12, 706902.	2.3	61
21	Using enzymatic numerical P systems for modeling mobile robot controllers. <i>Natural Computing</i> , 2012, 11, 387-393.	3.0	60
22	Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers. <i>Frontiers in Immunology</i> , 2020, 11, 1768.	4.8	58
23	Serum from Asian patients with atopic dermatitis is characterized by TH2/TH22 activation, which is highly correlated with nonlesional skin measures. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 324-328.e11.	2.9	52
24	RNA Sequencing Keloid Transcriptome Associates Keloids With Th2, Th1, Th17/Th22, and JAK3-Skewing. <i>Frontiers in Immunology</i> , 2020, 11, 597741.	4.8	51
25	Phase 2a randomized clinical trial of dupilumab (anti-IL4R α) for alopecia areata patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 897-906.	5.7	51
26	Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 63-70.	1.2	42
27	Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 370-380.	1.2	42
28	Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 122, 318-330.e3.	1.0	40
29	An integrated model of alopecia areata biomarkers highlights both TH1 and TH2 upregulation. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1631-1634.e13.	2.9	38
30	Kallikrein 7 Promotes Atopic Dermatitis-Associated Itch Independently of Skin Inflammation. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1244-1252.e4.	0.7	36
31	COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 134-142.	3.8	34
32	Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2095-2107.	2.9	33
33	Alterations in Bronchial Airway miRNA Expression for Lung Cancer Detection. <i>Cancer Prevention Research</i> , 2017, 10, 651-659.	1.5	31
34	Proteomic analysis from skin swabs reveals a new set of proteins identifying skin impairment in atopic dermatitis. <i>Experimental Dermatology</i> , 2021, 30, 811-819.	2.9	30
35	Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1318-1328.	2.9	30
36	SARS-CoV-2 receptor ACE2 protein expression in serum is significantly associated with age. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 875-878.	5.7	29

#	ARTICLE	IF	CITATIONS
37	On the power of enzymatic numerical P systems. <i>Acta Informatica</i> , 2012, 49, 395-412.	0.5	28
38	Major Differences in Expression of Inflammatory Pathways in Skin from Different Body Sites of Healthy Individuals. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2228-2232.e10.	0.7	25
39	Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity. <i>BMC Systems Biology</i> , 2016, 10, 16.	3.0	24
40	Integrating mutation and gene expression cross-sectional data to infer cancer progression. <i>BMC Systems Biology</i> , 2016, 10, 12.	3.0	24
41	Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3107-3121.	5.7	23
42	Immune and barrier characterization of atopic dermatitis skin phenotype in Tanzanian patients. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 334-341.	1.0	23
43	Mapping atopic dermatitis and anti-IL-22 response signatures to type 2 low severe neutrophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 89-101.	2.9	22
44	Universality of Enzymatic Numerical P systems. <i>International Journal of Computer Mathematics</i> , 2013, 90, 869-879.	1.8	16
45	A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1847-1851.	0.7	16
46	Transcriptomic Profiling of Tape-Strips From Moderate to Severe Atopic Dermatitis Patients Treated With Dupilumab. <i>Dermatitis</i> , 2021, 32, S71-S80.	1.6	16
47	Improving evaluation of drugs in atopic dermatitis by combining clinical and molecular measures. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3622-3625.e19.	3.8	15
48	Comparing cutaneous molecular improvement with different treatments in atopic dermatitis patients. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1285-1288.	2.9	15
49	An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3053-3065.	5.7	15
50	The role of circulating eosinophils on COVID-19 mortality varies by race/ethnicity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 925-927.	5.7	14
51	Tape-strips provide a minimally invasive approach to track therapeutic response to topical corticosteroids in atopic dermatitis patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 576-579.e3.	3.8	13
52	A Preliminary 18F-FDG-PET/MRI Study Shows Increased Vascular Inflammation in Moderate-to-Severe Atopic Dermatitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3500-3506.	3.8	12
53	Transcriptomic Analysis of the Major Orphan Ichthyosis Subtypes Reveals Shared Immune and Barrier Signatures. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2363-2374.e18.	0.7	11
54	Tape strips capture atopic dermatitis-related changes in nonlesional skin throughout maturation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3445-3447.	5.7	11

#	ARTICLE	IF	CITATIONS
55	The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 734-736.	1.0	10
56	Identifying cancer type specific oncogenes and tumor suppressors using limited size data. <i>Journal of Bioinformatics and Computational Biology</i> , 2016, 14, 1650031.	0.8	9
57	Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1657-1660.	1.2	8
58	A Nitric Oxide-Releasing Topical Medication as a Potential Treatment Option for Atopic Dermatitis through Antimicrobial and Anti-Inflammatory Activity. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2531-2535.e2.	0.7	8
59	Arsenic and chromium levels in hair correlate with actinic keratosis/non melanoma skin cancer: results of an observational controlled study. <i>Italian Journal of Dermatology and Venereology</i> , 2020, , .	0.2	8
60	Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes. <i>British Journal of Dermatology</i> , 2022, 187, 539-547.	1.5	7
61	High-dimensional analysis defines multicytokine T cell subsets and supports a role for IL-21 in atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3080-3093.	5.7	6
62	Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 551-562.	1.2	6
63	Th1, Th2 and Th17 inflammatory pathways synergistically predict cardiometabolic protein expression in serum of COVID-19 patients. <i>Molecular Omics</i> , 2022, , .	2.8	4
64	A pan-cancer analysis of progression mechanisms and drug sensitivity in cancer cell lines. <i>Molecular Omics</i> , 2019, 15, 399-405.	2.8	2